Bioglan Solaraze deals

Bioglan (LSE:BGP) sold its U.S., Canadian and Mexican marketing rights for Solaraze diclofenac, a non-steroidal anti-inflammatory drug to treat actinic keratosis, to Quintiles (QTRN) for L15 million ($22 million). BGP originally bought the Solaraze rights from SkyePharma (LSE:SKP; SKYE) in 2000. In November, SKP notified BGP that it wanted to terminate the marketing deal. ...